EP2037936A2 — Method of treating and preventing secondary hyperparathyroidism

USPTO Abstract

A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25 -hydroxy vitamin D and 1, 25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25 -hydroxy vitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1, 25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1, 25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25- hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1, 25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25- hydroxyvitamin D during treatment comprises predominantly 25 -hydroxy vitamin D3, and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D3 for 25 -hydroxy vitamin D repletion and/or maintenance